Date Initiated by Firm | January 30, 2007 |
Date Posted | April 05, 2007 |
Recall Status1 |
Terminated 3 on August 10, 2011 |
Recall Number | Z-0722-2007 |
Recall Event ID |
37334 |
510(K)Number | K981759 |
Product Classification |
in vitro diagnostic - Product Code CEO
|
Product | Clinical Chemistry Phosphorus in vitro diagnostic, List Number: 7D71-30 and 7D71-20 |
Code Information |
42020HW00 & 44037HW00 |
Recalling Firm/ Manufacturer |
Abbott Laboratories Inc. 820 Mission St South Pasadena CA 91030-3142
|
For Additional Information Contact | Irene Powers 847-937-1998 |
Manufacturer Reason for Recall | Patient results are falsely decreased by up to 15% at these levels: 1) Serum Plasma phosphorus greater than 8.0 mg/dL (2.60 mmol/L) 2) Urine phosphorus greater than 80.0 mg/dL (25.80 mmol/L) |
FDA Determined Cause 2 | Other |
Action | A Product Correction letter dated January 30, 2007 provided to all Clinical Chemistry Phosphorus customers that have received lot numbers 42020HW00 and 44037HW00 stating that patient results are falsely decreased by up to 15% at these levels: Serum/Plasma phosphorus greater than 8.0 mgldL (2.60 mmol/L) and Urine phosphorus greater than 80.0 mg/dl. (25.80 mmol/L). Modified linearity ranges are provided in the letter that are to be implemented when using the two lots. Instructions are also provided for changing the linearity range on the Architect cSystem as well as the Aeroset System. Customers are instructed that If they have forwarded any of Information the Clinical Chemistry Phosphorus lots listed above to another laboratory to provide a copy of this letter to them. A customer response form is provided. |
Quantity in Commerce | 42020HW00 - 1,351 units worldwide; 44037HW00 - 314 units worldwide |
Distribution | Worldwide, including USA, Canada, Trinidad & Tobago, Bahamas, Panama, Cayman Islands, Jamaica |
Total Product Life Cycle | TPLC Device Report |
|
1 A record in this database is created when a firm initiates a correction or removal action. The record is updated if the FDA identifies a violation and classifies the action as a recall, and it is updated for a final time when the recall is terminated. Learn more about medical device recalls. 2 Per FDA policy, recall cause determinations are subject to modification up to the point of termination of the recall. 3 For details about termination of a recall see Code of Federal Regulations (CFR) Title 21 §7.55.
|
510(K) Database | 510(K)s with Product Code = CEO
|